



Published in final edited form as:

*Pestic Biochem Physiol.* 2010 June 1; 97(2): 87–92. doi:10.1016/j.pestbp.2009.09.001.

## Mechanism of action of sodium channel blocker insecticides (SCBIs) on insect sodium channels

Kristopher S. Silver<sup>1</sup>, Weizhong Song<sup>1</sup>, Yoshiko Nomura<sup>1</sup>, Vincent L. Salgado<sup>2,\*</sup>, and Ke Dong<sup>1,\*</sup>

<sup>1</sup>Department of Entomology, Genetics and Neuroscience Programs, Michigan State University, East Lansing, MI, 48824, USA

<sup>2</sup>BASF Agricultural Products, BASF Corporation, 26 Davis Drive, Research Triangle Park, NC 27709, USA

### Abstract

Sodium channel blocker insecticides (SCBIs) are a relatively new class of insecticides, with a mechanism of action different from those of other classes of insecticides that target voltage-gated sodium channels. These compounds have no effect at hyperpolarized membrane potentials, but cause a voltage-dependent, nearly irreversible block as the membrane potential is depolarized. The mechanism of action of SCBIs is similar to that of local anesthetics (LAs), class I anticonvulsants and class I antiarrhythmics. In this article, we review the physiological actions of these compounds on the whole animal, the nervous system and sodium channels, and also present the results from recent studies that elucidate the receptor site of SCBIs.

### Introduction

Voltage-gated sodium channels are responsible for the initiation and propagation of action potentials in almost all excitable cells. They are well known as the primary target of DDT, naturally occurring pyrethrins found in extracts of the flowers of *Chrysanthemum* species, and modern synthetic pyrethroids, which are structural derivatives of pyrethrins [1]. Furthermore, this large, functionally complex channel protein is known to possess at least nine independent target sites for a variety of neurotoxins produced by plants and animals for defense or predation [2, 3], such as tetrodotoxin,  $\alpha$  and  $\beta$ -scorpion toxins, and batrachotoxin. While it has long been known that many therapeutically useful local anesthetic, antiarrhythmic and anticonvulsant drugs block the sodium channel by occluding its pore, no compounds acting by that mechanism showed insecticidal properties, until the discovery of pyrazolines (also known as dihydropyrazoles) [4, 5]. These insecticides, along with the more recently derived indoxacarb and metaflumizone, are collectively called sodium channel blocker insecticides (SCBIs) [6]. Benzhydropiperidines, discovered at FMC corporation and chemically unrelated to the pyrazolines, cause similar symptoms to pyrazolines and appear to have the same mode of action [7].

© 2009 Elsevier Inc. All rights reserved.

\*Corresponding authors: Ke Dong: dongk@msu.edu; Vincent L. Salgado: vincent.salgado@basf.com.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Chemical evolution of SCBIs

The history and development of the SCBIs leading to indoxacarb has recently been reviewed [6, 8, 9]. The first insecticidal pyrazoline sodium channel blockers, represented by PH 60-41, were highly active against coleopteran and lepidopteran pests [10], and the addition of a phenyl ring at the 4-position of the pyrazoline ring, as in PH-60-42, led to even greater activity (Fig. 1) [11], but the compounds had problems with environmental persistence, long-term toxicity and bioaccumulation [12]. The 4-methyl, 4-carbomethoxy pyrazolines, such as RH3421, had high insecticidal efficacy and more rapid environmental degradation [13, 14], but still had a problem with long-term mammalian toxicity [5]. Modifications to the pyrazoline nucleus by chemists at DuPont resulted in the discovery of several classes of related structures, all with similarly high levels of insecticidal activity. Expanding the pyrazoline ring by one oxygen atom and bridging the C-4 position with the C-3 aryl substituent gave highly-active oxadiazine compounds that were optimized to obtain indoxacarb, which controls a wide spectrum of insect pests, including many lepidoptera as well as plant bugs, leafhoppers, fleahoppers, weevils, beetles, flies, cockroaches and ants. Indoxacarb has excellent safety to mammals and other non-target organisms, and obtained a reduced-risk registration in 2000 [6, 8].

The semicarbazones are ring-opened pyrazolines discovered at Nihon Nohyaku Co., Ltd, by removing the carbon at the 5-position of the 3,4-diphenyl pyrazoline of the type of PH 60-42 [15]. Optimization of the semicarbazones led to metaflumizone, which is being co-developed globally by BASF SE, Fort Dodge Animal Health, a Division of Wyeth Corporation and Nihon Nohyaku Co., Ltd. Metaflumizone provides good to excellent control of most economically important lepidopterous pests and certain pests in the orders Coleoptera, Hemiptera, Hymenoptera, Diptera, Isoptera and Siphonaptera [16]. Metaflumizone provides long-lasting control of fleas on companion animals with a single spot-on application and is being marketed for this use under the trade name Promeris by Fort Dodge Animal Health, a Division of Wyeth. Indoxacarb and metaflumizone are the only SCBIs that have been commercialized to date.

Indoxacarb is a prodrug that requires metabolic activation by insects before it acts as a strong sodium channel blocker. An esterase or amidase cleaves the carbomethoxy group from the urea linkage, liberating the free urea (N-decarbomethoxylated DPX-MP062 or DCMP) which then acts as the voltage-dependent sodium channel blocker. This was first demonstrated for the racemic compound DPX-JW062 (50:50 mixture of active S and inactive R enantiomers) being converted to the corresponding N-decarbomethoxylated compound DCJW [17]. However it appears that all of the insecticidal activity resides in the S-enantiomer of DCJW [17], as has been observed for dihydropyrazoles [18].

## Block of spontaneous activity in the nervous system

Pyrazolines, indoxacarb and metaflumizone produce identical acute neurotoxic symptoms in insects, characterized by a distinctive pseudoparalysis, so named because poisoned insects appear to be paralyzed, but can move, sometimes violently, when disturbed [4, 6, 19]. Pseudoparalyzed cockroaches produce violent convulsions when disturbed, whereas lepidopteran larvae squirm and produce tremors of legs and mandibles that are evident upon microscopic examination. Higher doses of pyrazolines, especially in lepidopterous larvae, lead within a few hours to flaccid paralysis [4].

Pseudoparalysis is associated with a complete absence of spontaneous activity in the nervous system of insects poisoned by pyrazolines [4], indoxacarb or DCJW [17] or metaflumizone [19]. The complete absence of neural activity in poisoned insects indicates that SCBIs block not only tonic sensory receptors, but also pacemaker activity in the central

nervous system. Both of these effects involve action potential generation in regions of neurons that are able to generate action potentials repetitively in response to constant stimuli. The ability of phasic receptors to respond long after paralysis at a high dose suggests that phasic receptors are not as sensitive as the tonic ones [4].

Intracellular recordings from the abdominal slowly adapting stretch receptor neuron of the crayfish showed that pyrazolines increased the threshold for spike generation in response to depolarizing pulses, indicating that voltage-dependent sodium channels, whose activation determines the threshold and initiates the action potential, were blocked by pyrazolines [4]. Similar experiments showed an identical action of metaflumizone on neurons isolated from the CNS of *Manduca sexta* larvae [19].

### State-dependent block of sodium channels by SCBIs

Because axonal action potential conduction appeared to be relatively insensitive to pyrazolines, it was postulated that the compounds block sodium channels in a voltage-dependent manner, and are therefore selective for sodium channels in the spike initiation zone, where the resting potential is near the threshold for action potential generation, in the range of  $-70$  to  $-50$  mV. In contrast, axons rest near  $-90$  mV, where sodium channels spend most of their time in the resting state. When depolarized to the range where sodium channels begin to undergo conformational changes, axons become sensitive to pyrazolines [4]. Similarly, the extracellularly recorded compound action potential from motor nerves of *M. sexta* abdominal ganglia, which was likewise resistant to DCJW, was rendered sensitive by depolarization of the nerves with a high- $K^+$  saline [17]. Furthermore, Wing *et al.* (1998) showed that block of *M. sexta* compound action potentials by DCJW was stereospecific for the S-enantiomer, which is also the only enantiomer toxic to insects [17].

Voltage-clamp studies have confirmed that sodium channels are resistant to pyrazolines at highly negative potentials, but become sensitive when the cell is depolarized into the range where activation and inactivation occur [5, 20–22]. The transient natures of both open and activated states imply that the inactivated states of sodium channels are most likely to be sensitive to SCBIs. There are two partially independent inactivation processes, known as fast and slow inactivation. Fast inactivation occurs on a millisecond time scale and serves to terminate the action potential, whereas slow inactivation occurs on a much slower time scale, over hundreds of milliseconds, and performs a slow, modulatory function. Slow inactivation occurs at more negative potentials than fast inactivation, so that in the steady-state, channels are either resting or slow-inactivated. It appears that pyrazolines bind to the slow-inactivated state and effectively shift the slow inactivation curve to the left (Fig. 2) [5]. Whereas fast inactivation occurs with a time course of hundreds of microseconds to a few milliseconds, and slow inactivation on the order of tens to hundreds of milliseconds, the changes in peak sodium current in the presence of SCBIs occur on a much slower time scale, on the order of 15 minutes. This slow suppression of peak current in response to voltage change can therefore be attributed to binding and unbinding of SCBIs to sodium channels.

When the slow inactivation gate of sodium channels was removed by pretreatment of the internal face of the axon membrane with trypsin, block by the pyrazoline RH-1211 at  $-90$  mV was comparable to that in intact axons, indicating that RH-1211 can also block fast-inactivated channels. Pretreatment of axons with both trypsin to remove slow inactivation and the protein-modifying reagent N-bromoacetamide (NBA) yields sodium channels that do not inactivate. RH-1211 was just as potent at blocking these non-inactivating channels as intact channels, showing that it can also block open channels [5].

Although the SCBIs appear to enhance slow inactivation, it is important to realize that slow inactivation itself is not affected. Instead, slow inactivation appears to be enhanced because

of the addition to the system of the highly stable SCBI-bound slow-inactivated state. In the presence of the SCBI, time for this very slow equilibration of the drug with the receptors must be allowed in order to measure slow inactivation properly. It is not enough to simply measure slow inactivation with pulses long enough to attain a steady state in the absence of SCBI. While pulses on the order of 1 second are long enough to attain steady-state slow inactivation in control axons, 15 minutes are required in the presence of insecticide [5].

Recent studies provide evidence for action of SCBIs on more than one sodium channel subtype. The action of DCJW on sodium channels in dorsal unpaired median (DUM) neurons isolated from the CNS of *P. americana* has been studied with the patch clamp technique [23]. Action potentials in these pacemaking neurons were blocked by 100 nM DCJW, and this action was shown to be due to block of voltage-dependent sodium channels. The block was very potent, with an  $IC_{50}$  of 28 nM at  $-90$  mV, in good agreement with the  $IC_{50}$  of racemic DCJW of 40 nM in blocking the compound action potential in *Manduca sexta* CNS determined by Wing *et al.* (1998) [17]. An additional effect on the *P. americana* DUM neurons observed by Lapied *et al.* (2001) [23] was a strong hyperpolarization of the resting potential associated with an increase in membrane resistance, indicating block of a depolarizing conductance thought to be the background sodium channels involved in the maintenance of the resting potential [24, 25]. This finding is interesting and should be investigated in more detail, because it demonstrates the existence of sodium channel variants that may have different sensitivities to insecticides. Consistent with this hypothesis, Zhao *et al.* (2005) identified two types of TTX-sensitive sodium currents in cockroach neurons that exhibited distinct voltage dependencies of inactivation and differential sensitivities to indoxacarb and DCJW [26]. Furthermore, two cockroach sodium channel variants, BgNa<sub>v</sub>1-1 and BgNa<sub>v</sub>1-4, also exhibited different gating properties and differential sensitivities to DCJW [27]. A lysine to glutamic acid change (K1689E) in IVS4 of BgNa<sub>v</sub>1-4 was identified as being responsible for both the enhanced sensitivity of BgNa<sub>v</sub>1-4 to DCJW and large negative shifts in the voltage-dependencies of both the fast and slow inactivation gating of this channel variant.

### SCBIs bind within the sodium channel pore

The blocking action of pyrazolines on voltage-dependent sodium channels was recognized as being similar to that of local anesthetics (LAs), class I anticonvulsants and class I antiarrhythmics [5], a structurally broad range of drugs [28, 29] all known to act at a common blocker site within the sodium channel pore. Like the SCBIs, drugs acting at the local anesthetic site all exhibit voltage dependence of block deriving from selective binding to open and inactivated channel states. Biochemical and pharmacological evidence indicates possible overlapping binding sites between these two classes of sodium channel blockers. Local anesthetics displace [<sup>3</sup>H]-Batrachotoxin-B (BTX) from its binding site in the sodium channel [30, 31]. The interaction is allosteric, because local anesthetics can block BTX-modified open channels without displacing the toxin, [32, 33], although they speed the dissociation of BTX from its binding site. Pyrazolines were also shown to potently displace specific binding of [<sup>3</sup>H]-BTX-B [5, 34]. Payne *et al.* (1998) further examined the interaction between the pyrazoline RH-3421 and the local anesthetic dibucaine in BTX binding studies [35]. Each of these compounds decreased the potency of the other as an inhibitor of BTX binding, approximately as much as expected from the assumption that they share a common binding site. Furthermore, like local anesthetics, RH-3421 increased the dissociation rate of [<sup>3</sup>H]-BTX-B from its binding site [34]. Finally, in voltage-clamp studies in oocytes, phenytoin, an anticonvulsant, decreased the inhibitory activity of DCJW when applied in tandem [20].

Lapied *et al.* (2001) examined the interactions of DCJW with the local anesthetic lidocaine and the guanidinium blocker tetrodotoxin (TTX), using dorsal unpaired median (DUM) neurons isolated from the CNS of *P. Americana* [23]. TTX is known to block the pore at a binding site that is distinct from the binding site of the local anesthetics [2, 3, 36]. The IC<sub>50</sub> for DCJW was not affected by the presence of an IC<sub>50</sub> concentration of TTX in the external solution, consistent with independent action of the two compounds at distinct binding sites. In the presence of an IC<sub>50</sub> concentration of lidocaine, however, the IC<sub>50</sub> for DCJW was increased about 30-fold. A 2-fold shift in equilibrium binding would be expected from the hypothesis that both compounds act at the same site [37], so the mechanism of the observed 30-fold shift is not fully understood. Nevertheless, available evidence is consistent with the action of the SCBIs at or near the local anesthetic site.

## Molecular basis of the binding and action of SCBIs

Recent studies using insect and mammalian sodium channels expressed in the *Xenopus* oocyte expression system have begun to reveal the sodium channel interactions of SCBIs at the molecular level [38, 39]. Sodium channels consist of four homologous domains (I–IV), each containing six transmembrane segments (S1–S6) connected by extra- and intracellular loops [40, 41]. Site-directed mutagenesis of mammalian sodium channels identified a number of residues in the S6 transmembrane segments of domains I, III, and IV that are critical for the binding and action of a variety of therapeutic sodium channel blockers [42–49]. In particular, two residues in IVS6, F1579 and Y1586 (numbered according to their location in the rat Na<sub>v</sub>1.4 sodium channel) are key residues in the binding and action of these therapeutic drugs including LAs (Fig. 3) [42, 50]. The notion of potentially overlapping binding sites for LAs and SCBIs on sodium channels prompted an evaluation of the involvement of these two residues in the action of RH3421, indoxacarb, and DCJW in a recent study by Silver and Soderlund (2007) using the Na<sub>v</sub>1.4 sodium channel expressed in *Xenopus* oocytes [38]. Alanine substitution at F1579 in Na<sub>v</sub>1.4 resulted in a significant reduction in the ability of DCJW and RH3421 to inhibit Na<sub>v</sub>1.4 sodium channels expressed in *Xenopus* oocytes [38]. In contrast, alanine substitution of the tyrosine residue at position 1586 (Y1586A) in Na<sub>v</sub>1.4 channels resulted in a significant increase in the potency of indoxacarb, DCJW, and RH3421 [38]. It appears that the phenylalanine residue in IVS6 provides a crucial aromatic-aromatic interaction with the drug/insecticide molecule in mammalian sodium channels, whereas the tyrosine residue, while providing important pi-electron interactions for local anesthetics, appears to interfere with SCBI activity since its removal enhances insecticide activity [38, 51].

To examine the roles of F1817 and Y1824 in IVS6 (homologous to F1579 and Y1586 in rat Na<sub>v</sub>1.4) in the interactions of insect sodium channels with SCBIs, alanine substitutions of F1817 and Y1824 were introduced into a DCJW-sensitive cockroach sodium channel variant, BgNa<sub>v</sub>1-1A [39]. The effects of alanine substitutions on the action of indoxacarb, DCJW and metaflumizone were examined. The blocking activities of two SCBIs on the wildtype and mutant cockroach sodium channels were determined using two different recording protocols, one assessing the onset of block at a depolarizing potential (close to V<sub>0.5</sub> of slow inactivation) and the other determining block of fully-inactivated Na channels. The F1817A substitution had no effect on inhibition by indoxacarb or DCJW using either protocol. Unlike its role in the interaction of Na<sub>v</sub>1.4 channels with DCJW, the phenylalanine residue (F1817, corresponding to F1579 in Na<sub>v</sub>1.4) is not important for the action of DCJW on BgNa<sub>v</sub>1-1A sodium channels. On the other hand, the F1817A substitution enhanced the inhibition by metaflumizone, as measured by the onset of block at half inactivation, and accelerated the recovery of F1817A channels from metaflumizone block at hyperpolarized potentials. Therefore, although the F1817 residue is not an SCBI-binding residue in BgNa<sub>v</sub>1-1A channels, the replacement of its aromatic side chain with a smaller side chain

appears to allow metaflumizone (but not DCJW) to get in and out of its receptor site more readily.

As mentioned above, in rat Na<sub>v</sub>1.4 sodium channels, alanine substitution of the tyrosine residue caused a 58-fold increase in inhibition by DCJW of Na<sub>v</sub>1.4 channels that were completely inactivated [38]. However, alanine substitution of the corresponding residue, Y1824, in IVS6 of BgNa<sub>v</sub>1-1A did not have a significant effect on inhibition by DCJW or metaflumizone in conditions that did not permit complete equilibration between insecticide and channel [39]. In contrast, results from the recovery from slow inactivation assay, in which inactivated channels were able to completely equilibrate with insecticide, show that inactivated BgNa<sub>v</sub>1-1A<sup>Y1824A</sup> channels have a higher affinity to both DCJW and metaflumizone than wildtype channels. Thus, the Y1824 residue does not play a role in SCBI activity. Furthermore, the SCBI receptor in insect sodium channels appears to be formed by residues distinct from those in mammalian sodium channels.

### Mechanism of action of lidocaine on an insect sodium channel

In contrast to mammalian sodium channels, the molecular determinants of local anesthetic action on insect sodium channels have not been identified. Song *et al.* evaluated the effects of lidocaine on wildtype (BgNa<sub>v</sub>1-1A) sodium channels and the effects of the mutations F1817A and Y1824A of IVS6 on the activity of lidocaine on BgNa<sub>v</sub>1-1A sodium channels (unpublished data, manuscript in preparation). Lidocaine blocked BgNa<sub>v</sub>1-1A sodium channels and rat Na<sub>v</sub>1.2 sodium channels in the resting state (i.e., tonic block) with similar potency [52]. However, a significant difference in the effects of lidocaine on mammalian and insect sodium channels was observed. Use-dependent and frequency-dependent block of mammalian sodium channels are key features of local anesthetic block and are vital for the clinical use of LA drugs. This effect is explained by a modulated drug receptor that has a low affinity for channels in resting states, but a higher affinity for channels in open or inactivated states [53, 54]. However, lidocaine caused very little use-dependent and frequency-dependent inhibition of BgNa<sub>v</sub>1-1A sodium channels (unpublished data). This difference could be due to faster recovery from inactivation of BgNa<sub>v</sub>1-1A sodium channels consequently reducing the availability of inactivated states for the action of lidocaine [23].

Nevertheless, residues in the cockroach sodium channel corresponding to the LA-interacting residues in IVS6 also contribute to the action of lidocaine on BgNa<sub>v</sub>1-1A channels, albeit to a minor extent. Specifically, BgNa<sub>v</sub>1-1A<sup>F1817A</sup> and BgNa<sub>v</sub>1-1A<sup>Y1824A</sup> sodium channels exhibited smaller lidocaine-induced hyperpolarizing shifts in the voltage dependence of slow inactivation than BgNa<sub>v</sub>1-1A channels (unpublished data). However, the tonic block was not affected by these substitutions, in contrast to previous studies with mammalian sodium channels, for which the F1710A mutation (in Na<sub>v</sub>1.3) also reduced the resting-state affinity [42, 43, 50, 55]. Taken together, these results suggest that F1817A and Y1824A substitutions attenuate the activity of lidocaine in the cockroach BgNa<sub>v</sub>1-1A channel, possibly by reducing the binding affinity of lidocaine to the slow-inactivated state.

In conclusion, SCBIs are hypothesized to bind at or near the LA-binding site on mammalian and insect sodium channels. This hypothesis predicts that LA-binding residues, particularly a phenylalanine (F1579) and a tyrosine (Y1586) in IVS6 of the mammalian Na<sub>v</sub>1.4 channel, would be required for the action of metaflumizone, indoxacarb, and DCJW. In support of this hypothesis, alanine substitution of the LA-binding residue F1579 results in reduced sensitivity of the mammalian sodium channel Na<sub>v</sub>1.4 to DCJW, [38]. However, results from the analysis of an insect sodium channel, as presented above, revealed that the corresponding residues are not of primary importance to the action of SCBIs in insect sodium channels [39]. Our results raise the intriguing possibility that the receptor for SCBIs,

and possibly local anesthetics, is determined by a different subset of amino acid residues in insect sodium channels than in mammalian sodium channels. Future site-directed mutagenesis of other regions of insect sodium channels is necessary to identify key molecular determinants of the SCBI binding site on insect sodium channels.

## Mechanism of insect selectivity of SCBIs

Insect selectivity and mammalian safety of modern SCBIs is achieved through a combination of selective metabolism and selective action at the target site. The pyrazoline RH-3421 had an  $IC_{50}$  of 270 nM for rat brain Na channels, as measured by displacement of radiolabeled batrachotoxin B. In crayfish giant axons, the  $IC_{50}$  for binding to the slow-inactivated state, measured by voltage clamp was 680 nM [5]. The potency in blocking CNS and sensory activity in various insect preparations was also in this range [4]. This lack of insect selectivity of the pyrazolines at the target site and their potential for bioaccumulation contributed to the toxicological problems that prevented their development [5].

In contrast to the pyrazolines, indoxacarb, the first SCBI to be commercialized, has an excellent toxicological profile and received a reduced-risk registration [56]. Indoxacarb was designed as a prodrug, and is selectively metabolized by hydrolases in insects to DCJW [17], which is only a minor pathway in higher animals, where inactivation via P450-mediated attack of the indanone and oxadiazine rings is favored [56]. Furthermore, DCJW is significantly more potent against insect than mammalian sodium channels: whereas it blocks the rat  $Na_v1.4$  channel with an  $IC_{50}$  of 1000 nM [38], it is 40-fold more potent against the Bg  $Na_v1-1a$  channel, with an  $IC_{50}$  of 25.5 nM [39]. Metaflumizone likewise offers low risk to mammals, beneficial insects and other non-target organisms [57], but the mechanisms of insect selectivity have not been investigated.


## References

1. Narahashi, T. Molecular and cellular approaches to neurotoxicology: past, present, and future. In: Lunt, G., editor. Neurotoxicology 1988: Molecular Basis of Drug and Pesticide Action. Elsevier; New York: 1988. p. 563-582.
2. Cestele S, Catterall WA. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. *Biochimie*. 2000; 82:883–892. [PubMed: 11086218]
3. Wang SY, Wang GK. Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins. *Cell Signal*. 2003; 15:151–159. [PubMed: 12464386]
4. Salgado VL. Mode of action of insecticidal dihydropyrazoles: selective block of impulse generation in sensory nerves. *Pestic Sci*. 1990; 28:389–411.
5. Salgado VL. Slow voltage-dependent block of sodium channels in crayfish nerve by dihydropyrazole insecticides. *Mol Pharmacol*. 1992; 41:120–126. [PubMed: 1310138]
6. Wing, KD.; Andalaro, JT.; McCann, SF.; Salgado, VL. Indoxacarb and the sodium channel blocker insecticides: chemistry, physiology, and biology in insects. In: Gilbert, LI.; Iatrou, K.; Gill, SS., editors. *Comprehensive Molecular Insect Science*. Vol. 6. Elsevier; New York: 2005. p. 30-53.
7. Bloomquist JR, Payne GT, Kinne L, Lyga J, Leong D, Nicholson RA. Toxicity and mode of action of benzhydropiperidines and related compounds in insects. *Pestic Biochem Physiol*. 2002; 73:18–26.
8. McCann, SF.; Cordova, D.; Andalaro, JT.; Lahm, GP. Sodium channel blocking insecticides. In: Kraemer, W.; Schirmer, U., editors. *Modern Crop Protection Compounds*. Vol. 3. Wiley-VCH; Weinheim: 2007. p. 1031-1048.
9. Silver K, Soderlund DM. Action of pyrazoline-type insecticides at neuronal target sites. *Pestic Biochem Physiol*. 2005; 81:136–143.
10. Mulder R, Wellinga K, van Daalen JJ. A new class of insecticides. *Naturwissenschaften*. 1975; 62:531–532. [PubMed: 1214852]

11. Grosscurt AC, van Hes R, Wellinga K. 1-Phenylcarbamoyl-2-pyrazolines, a new class of insecticides. 3. Synthesis and insecticidal properties of 3,4-diphenyl-1-phenylcarbamoyl-2-pyrazolines. *J Agric Food Chem*. 1979; 27:406–409.
12. Meier, GA.; Silverman, IR.; Ray, PS.; Cullen, TG.; Ali, SF.; Marek, FL.; Webster, CA. Insecticidal dihydropyrazoles with reduced lipophilicity. In: Baker, DR.; Fenyes, JG.; Steffens, JJ., editors. *Synthesis and Chemistry of Agrochemicals III*. American Chemical Society; Washington D.C.: 1992. p. 313-326.
13. Jacobson, RM. A new class of insecticidal dihydropyrazoles. In: Crombie, L., editor. *Recent Advances in the Chemistry of Insect Control II*. Royal Society of Chemistry; London: 1989. p. 206-211.
14. Jacobson, RM. N-aryl 3-aryl-4,5-dihydro-1H-pyrazole-2-pyrazolines. US Patent. 5 798 311. 1985.
15. Takagi K, Hamaguchi H, Nishimatsu T, Konno T. Discovery of metaflumizone, a novel semicarbazone insecticide. *Veterinary Parasitology*. 2007; 150:177–181. [PubMed: 17980491]
16. Metaflumizone Worldwide Technical Brochure. 2007. BASF Agricultural Products.
17. Wing KD, Schnee ME, Sacher M, Connair M. A novel oxadiazine insecticide is bioactivated in lepidopteran larvae. *Arch Insect Biochem Physiol*. 1998; 37:91–103.
18. Hasan R, Nishimura K, Okada M, Akamatsu M, Inoue M, Ueno T, Taga T. Stereochemical basis for the insecticidal activity of carbamoylated and acylated pyrazolines. *Pestic Sci*. 1996; 46:105–112.
19. Salgado VL, Hayashi JH. Metaflumizone is a novel sodium channel blocker insecticide. *Veterinary Parasitology*. 2007; 150:182–189. [PubMed: 17959312]
20. Silver K, Soderlund DM. State-dependent block of rat Na<sub>v</sub>1.4 sodium channels expressed in *Xenopus* oocytes by pyrazoline-type insecticides. *Neurotoxicology*. 2005; 26:397–406. [PubMed: 15935211]
21. Zhao X, Ikeda T, Yeh JZ, Narahashi T. Voltage-dependent block of sodium channels in mammalian neurons by the oxadiazine insecticide indoxacarb and its metabolite DCJW. *Neurotoxicology*. 2003; 24:83–96. [PubMed: 12564385]
22. Wing KD, Sacher M, Kagaya Y, Tsurubuchi Y, Mulderig L, Connair M, Schnee ME. Bioactivation and mode of action of the oxadiazine indoxacarb in insects. *Crop Protect*. 2000; 19:537–545.
23. Lapiéd B, Grolleau F, Sattelle DB. Indoxacarb, an oxadiazine insecticide, blocks insect neuronal sodium channels. *Br J Pharmacol*. 2001; 132:587–595. [PubMed: 11159709]
24. Lapiéd B, Malecot CO, Pelhate M. Ionic species involved in the electrical activity of single adult aminergic neurons isolated from the sixth abdominal ganglion of the cockroach, *Periplaneta americana*. *J Exp Biol*. 1989; 144:535–550.
25. Lapiéd B, Stankiewicz M, Grolleau F, Rochat H, Zlotkin E, Pelhate M. Biophysical properties of scorpion alpha-toxin-sensitive background sodium channel contributing to the pacemaker activity in insect neurosecretory cells (DUM neurons). *Eur J Neurosci*. 1999; 11:1449–1460. [PubMed: 10103139]
26. Zhao X, Ikeda T, Salgado VL, Yeh JZ, Narahashi T. Block of two subtypes of sodium channels in cockroach neurons by indoxacarb insecticides. *Neurotoxicology*. 2005; 26:455–465. [PubMed: 15935215]
27. Song WZ, Liu ZQ, Dong K. Molecular basis of differential sensitivity of insect sodium channels to DCJW, a bioactive metabolite of the oxadiazine insecticide indoxacarb. *Neurotoxicology*. 2006; 27:237–244. [PubMed: 16325912]
28. Clare JJ, Tate SN, Nobbs M, Romanos MA. Voltage-gated sodium channels as therapeutic targets. *Drug Discov Today*. 2000; 5:506–520. [PubMed: 11084387]
29. Anger T, Madge DJ, Mulla M, Riddall D. Medicinal Chemistry of neuronal voltage-gated sodium channel blockers. *J Med Chem*. 2001; 44:115–137. [PubMed: 11170622]
30. Postma W, Catterall WA. Inhibition of [<sup>3</sup>H]batrachotoxinin A 20- $\alpha$ -benzoate binding to sodium channels by local anesthetics. *Mol Pharmacol*. 1984; 25:219–227. [PubMed: 6321944]
31. Catterall WA. Common modes of drug action of Na<sup>+</sup> channels: local anesthetics, antiarrhythmics, and anticonvulsants. *Trends Pharmacol Sci*. 1987; 8:57–65.


32. Wasserstrom JA, Liberty K, Kelly J, Santucci P, Myers M. Modification of cardiac sodium channels by batrachotoxin: effects on gating, kinetics, and local anesthetic binding. *Biophys J*. 1993; 65:386–395. [PubMed: 8396458]
33. Zamponi GW, Doyle DD, French RJ. Fast lidocaine block of cardiac and skeletal muscle sodium channels: one site with two routes of access. *Biophys J*. 1993; 65:80–90. [PubMed: 8396459]
34. Deecher DC, Payne GT, Soderlund DM. Inhibition of [<sup>3</sup>H]batrachotoxinin A 20- $\alpha$ -benzoate binding to mouse brain sodium channels by the dihydropyrazole insecticide RH 3421. *Pestic Biochem Physiol*. 1991; 41:265–273.
35. Payne GT, Deecher DC, Soderlund DM. Structure-activity relationships for the action of dihydropyrazole insecticides on mouse brain sodium channels. *Pestic Biochem Physiol*. 1998; 60:177–185.
36. Soderlund, DM. *Comprehensive Molecular Insect Science*. Vol. 5. Elsevier; New York: 2005. Sodium Channels; p. 1-24.
37. Cheng YC, Prusoff WH. Relationship between the inhibition constant and the concentration of inhibitor which causes 50 percent inhibition of an enzymatic reaction. *Biochemical Pharmacology*. 1973; 22:3099–3108. [PubMed: 4202581]
38. Silver K, Soderlund DM. Point Mutations at the Local Anesthetic Receptor Site Modulate the State-Dependent Block of Rat Na<sub>v</sub>1.4 Sodium Channels by Pyrazoline-type Insecticides. *Neurotoxicology*. 2007; 28:655–663. [PubMed: 17367864]
39. Silver K, Song W, Nomura Y, Salgado VL, Dong K. The role of the sixth transmembrane segment of domain IV of the cockroach sodium channel in the action of lidocaine and sodium channel blocker insecticides. *Neurotoxicology*. 2009; 30:613–621. [PubMed: 19443036]
40. Catterall WA. From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. *Neuron*. 2000; 26:13–25. [PubMed: 10798388]
41. Goldin AL. Resurgence of sodium channel research. *Annu Rev Physiol*. 2001; 63:871–894. [PubMed: 11181979]
42. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Molecular determinants of state-dependent block of Na<sup>+</sup> channels by local anesthetics. *Science*. 1994; 265:1724–1728. [PubMed: 8085162]
43. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na<sup>+</sup> channels. *Proc Natl Acad Sci*. 1996; 93:9270–9275. [PubMed: 8799190]
44. Yarov-Yarovoy V, Brown J, Sharp E, Clare JJ, Scheuer T, Catterall WA. Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na<sup>+</sup> channel  $\alpha$  subunit. *J Biol Chem*. 2001; 276:20–27. [PubMed: 11024055]
45. Yarov-Yarovoy V, McPhee JC, Idsvoog D, Pate C, Scheuer T, Catterall WA. Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na<sup>+</sup> channel  $\alpha$  subunit in voltage-dependent gating and drug block. *J Biol Chem*. 2002; 277:35393–35401. [PubMed: 12130650]
46. Nau C, Wang SY, Strichartz GR, Wang GK. Point mutations at N434 in D1-S6 of  $\mu$ 1 Na<sup>+</sup> channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers. *Mol Pharmacol*. 1999; 56:404–413. [PubMed: 10419561]
47. Wang GK, Quan C, Wang SY. A common local anesthetic receptor for benzocaine and etidocaine in voltage-gated  $\mu$ 1 Na<sup>+</sup> channels. *Eur J Physiol*. 1998; 435:293–302.
48. Wang SY, Nau C, Wang GK. Residues in Na<sup>+</sup> channel D3-S6 segment modulate batrachotoxin and local anesthetic affinities. *Biophys J*. 2000; 79:1379–1387. [PubMed: 10969000]
49. Wang GK, Russell C, Wang SY. State-dependent block of voltage-gated Na<sup>+</sup> channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. *Pain*. 2004; 110:166–174. [PubMed: 15275764]
50. Liu G, Yarov-Yarovoy V, Nobbs M, Clare JJ, Scheuer T, Catterall WA. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. *Neuropharmacology*. 2003; 44:413–422. [PubMed: 12604088]
51. Lipkind GM, Fozzard HA. Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. *Mol Pharmacol*. 2005; 68:1611–1622. [PubMed: 16174788]
52. Pugsley MK, Goldin AL. Effects of bisaramil, a novel class I antiarrhythmic agent, on heart, skeletal muscle and brain Na channels. *Eur J Pharmacol*. 1998; 342:93–104. [PubMed: 9544797]

53. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. *J Gen Physiol.* 1977; 69:497–515. [PubMed: 300786]
54. Hondeghem LM, Katzung BG. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. *Annual Review of Pharmacology and Toxicology.* 1984; 24:387–423.
55. Li HL, Galue A, Meadows L, Ragsdale DS. A molecular basis for the different local anesthetic affinities of resting versus open and inactivated states of the sodium channel. *Mol Pharmacol.* 1999; 55:134–141. [PubMed: 9882707]
56. EPA. Fact Sheet on Indoxacarb, Issued Oct 30, 2000. Environmental Protection Agency; Washington D.C.: 2000.
57. Hempel K, Hess FG, Boegi C, Fabian E, Hellwig J, Fegert I. Toxicological properties of metaflumizone. *Veterinary Parasitology.* 2007; 150:190–195. [PubMed: 17933467]



PH 60-41


(Philips-Duphar)



(Rohm and Haas)


**Figure 1.**

Structures of sodium channel blocker insecticides referred to in this article.



**Figure 2.**

Pyrazoline RH-3421 shifts the steady state slow inactivation curve in the direction of hyperpolarization. Ionic current traces were scaled by a common factor so that the peak at  $-120$  mV matched the peak before treatment. Peak  $I_{Na}$  was depressed most at depolarized potentials, whereas outward current,  $I_k$ , was not affected by the treatment. The graph shows plots of peak current normalized to the value at  $-120$  mV. RH-3421 ( $10 \mu\text{M}$ ) appears to shift the steady-state inactivation relation to the left by  $8.6$  mV [5].



**Figure 3.**

A. Helical wheel diagram showing all four homologous domains of BgNa<sub>v</sub>1-1a highlighting the relationship between the residues of IVS6 and a generic local anesthetic molecule. B. A side view of IVS6 showing the vertical orientation of a local anesthetic molecule to the F1817 and Y1824 residues of IVS6.